ScholarLens Back to search
2014•Journal watchRequires access

Improving the Prognostic Index for Diffuse Large B-Cell Lymphoma

Michael E. Williams

Open publisher page 0 citations

Abstract

The International Prognostic Index (IPI) has been a powerful tool for predicting post-treatment outcomes and comparing results across clinical trials in diffuse large B-cell lymphoma (DLBCL) for more than 20 years. Given that rituximab has improved survival across all risk groups since the late 1990s, investigators have created a new prognostic model based on a retrospective analysis of 1650 newly diagnosed DLBCL patients who received induction rituximab-based chemotherapy from 2000 to 2010 at seven centers in the National …

About this research paper

What this paper is about

The International Prognostic Index (IPI) has been a powerful tool for predicting post-treatment outcomes and comparing results across clinical trials in diffuse large B-cell lymphoma (DLBCL) for more than 20 years. Given that rituximab has improved survival across all risk groups since the late 1990s, investigators have created a new prognostic model based on a retrospective analysis of 1650 newly diagnosed DLBCL patients who received induction rituximab-based chemotherapy from 2000 to 2010 at seven centers in the National …

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The International Prognostic Index (IPI) has been a powerful tool for predicting post-treatment outcomes and comparing results across clinical trials in diffuse large B-cell lymphoma (DLBCL) for more than 20 years. Given that rituximab has improved survival across all risk groups since the late 1990s, investigators have created a new prognostic model based on a retrospective analysis of 1650 newly diagnosed DLBCL patients who received induction rituximab-based chemotherapy from 2000 to 2010 at seven centers in the National …

Key concepts: Rituximab, International Prognostic Index, Medicine, Diffuse large B-cell lymphoma, Lymphoma, Internal medicine, Oncology, Retrospective cohort study

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Improving the Prognostic Index for Diffuse Large B-Cell Lymphoma — Research Paper | ScholarLens